RETICULAR PSEUDODRUSEN ARE NOT A PREDICTIVE FACTOR FOR THE 1-YEAR RESPONSE TO INTRAVITREAL RANIBIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Issue 1 (January 2017)

• Record Type: Journal Article
• Authors: Nghiem-Buffet, Sylvia; Giocanti-Auregan, Audrey; Jung, Camille; Dubois, Lise; Dourmad, Pauline; Galbadon, Lea; Fajnkuchen, Franck; Quentel, Gabriel; Cohen, Salomon Y.
• Is Part Of: Retina. Volume 37:Issue 1(2017:Jan.)
• Publication Date: 2017-01
• Subjects: age-related macular degeneration -- reticular pseudodrusen -- choroidal thickness -- prognosis -- ranibizumab; Retina -- Diseases -- Periodicals; Retinal Diseases; Vitreous Body; 617.735
• DOI: 10.1097/IAE.0000000000001134
• Languages: English
• ISSNs: 0275-004X

Abstract

Abstract : Purpose: To investigate reticular pseudodrusen (RPD) as a potential baseline factor predictive of a poor 1-year response to intravitreal ranibizumab in eyes with neovascular age-related macular degeneration. Methods: Retrospective, monocentric case series including 98 consecutive naive neovascular age-related macular degeneration patients. Presence of RPD was assessed by two graders based on color, blue-light, fundus autofluorescence pictures, and spectral-domain optical coherence tomography. A correlation between the presence of RPD and the visual change was investigated. Other baseline characteristics studied in a monovariate and multivariate analysis were the following: age, gender, affected side, loading dose, type of neovascularization, presence of retinal pigment epithelial detachment >250 μ m, subretinal or intraretinal fluid, blood over >50% of the lesion, and subfoveal choroidal thickness. Results: The presence of RPD was not associated with a visual change ( P = 0.96), but with a thin subfoveal choroidal thickness at baseline ( P < 0.0001). The monovariate analysis showed that the presence of blood at baseline was associated with visual gain ( P = 0.007). Conclusion: The presence of RPD at baseline was not identified as a factor associated with a poor 1-year response to ranibizumab in eyes with neovascular age-related macular degeneration. Studies with a longer follow-up may be needed to assess the impact of RPD on the visual prognosis of eyes with neovascular age-related macular degeneration. Abstract : In a retrospective, monocentric, case series including 98 consecutive AMD patients with naive choroidal neovascularization treated with intravitreal ranibizumab, a monovariate and multivariate analysis of factors associated with visual change failed to identify the presence of reticular pseudodrusen as a factor associated with a poor visual outcome.